

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 4, 2023

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Joyce Frimpong, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Mark R. Conaway, PhD

Professor
Division of Translational Research and Applied
Statistics
Department of Public Health Sciences
The University of Virginia School of Medicine
Charlottesville, Virginia

William J. Gradishar, MD

Professor of Medicine/Betsy Bramsen Professor of
Breast Oncology
Chief, Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine at Northwestern
University
Chicago, Illinois

Christopher H. Lieu, MD

(Acting Chairperson)
Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology Program
University of Colorado
Aurora, Colorado

David E. Mitchell

(Consumer Representative)
President
Patients for Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC) Norris
Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Alberto S. Pappo, MD

Member, St. Jude Faculty
Director, Solid Tumor Division
Co-Leader, Developmental Biology & Solid Tumor
Program
Alvin Mauer Endowed Chair
St. Jude Children's Research Hospital
Memphis, Tennessee

Daniel Spratt, MD

Vincent K Smith Chair, Department of Radiation
Oncology
Professor of Radiation Oncology and Urology
University Hospitals Seidman Cancer Center
Case Western Reserve University
Cleveland, Ohio

Neil Vasan, MD, PhD

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 4, 2023

DRAFT MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Senior Vice President
Head of Oncology Development
Global Drug Development
Bristol-Myers Squibb
Lawrenceville, New Jersey

TEMPORARY MEMBERS (Voting)

G. Caleb Alexander, MD, MS

Professor of Epidemiology and Medicine
Center for Drug Safety and Effectiveness
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland

Shahab Asgharzadeh, MD

Associate Professor of Pediatrics
Director, Neuroblastoma Basic and Translational
Program
Children's Hospital Los Angeles
University of Southern California
Los Angeles, California

Mary Ellen Cosenza, PhD, DABT

Consultant
MEC Regulatory & Toxicology Consulting, LLC
Moorpark, California

Ami Desai, MD, MSCE

Associate Professor of Pediatrics
Section of Hematology, Oncology, and Stem Cell
Transplantation
The University of Chicago
Chicago, Illinois

AeRang Kim, MD, PhD

Director of Clinical Research
Division of Oncology
Children's National Hospital
Associate Professor of Pediatrics
The George Washington School of Medicine
Washington, District of Columbia

Gianna McMillan, DBE, MFA

(Patient Representative)
Los Angeles, California

Donald Williams (Will) Parsons, MD, PhD

Deputy Director
Texas Children's Cancer and Hematology Center
Professor of Pediatrics
Baylor College of Medicine
Houston, Texas

Pamela Shaw, PhD, MS

Senior Investigator
Biostatistics Division
Kaiser Permanente Washington Health Research
Institute
Seattle, Washington

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 4, 2023

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Til Stürmer, MD, MPH, PhD

Nancy A. Dreyer Distinguished Professor and Chair
Department of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Clare J. Twist, MD

Professor of Oncology
The Katie Dougherty Endowed Chair in Pediatric
Oncology
Director, Pediatric Developmental Therapeutics
Roswell Park Comprehensive Cancer Center
Oishei Children's Hospital
Buffalo, New York

Yoram Unguru, MD, MS, MA, HEC-C

Attending Physician
Division of Pediatric Hematology/Oncology
The Herman & Walter Samuelson Children's
Hospital at Sinai
Chairman, Sinai Hospital Ethics Committee
Core Faculty, Johns Hopkins Berman Institute of
Bioethics
Associate Professor, Johns Hopkins University
School of Medicine
Baltimore, Maryland

Brian Weiss, MD

Professor of Pediatrics
Chief, Division of Pediatrics
Hematology/Oncology/Stem Cell Transplant
Riley Hospital for Children
Indiana University
Indianapolis, Indiana

Brigitte Widemann, MD

Senior Investigator
Chief, Pediatric Oncology Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 4, 2023

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Office of the Commissioner (OC)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Paul Kluetz, MD

Deputy Center Director
OCE, OC
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Martha Donoghue, MD

Associate Director for Pediatric Oncology
OCE, OC, OOD, OND, CDER, FDA

Nicole Drezner, MD

Deputy Division Director
Division of Oncology 2 (DO2)
OOD, OND, CDER, FDA

Diana Bradford, MD

Cross Disciplinary Team Leader
DO2, OOD, OND, CDER, FDA

Elizabeth S. Duke, MD

Clinical Reviewer
DO2, OOD, OND, CDER, FDA

Arup Sinha, PhD

Statistics Reviewer
Division of Biometrics V
Office of Biostatistics
Office of Translational Sciences
CDER, FDA

Emily Wearne, PhD

Nonclinical Reviewer
Division of Hematology Oncology Toxicology
OOD, OND, CDER, FDA